Immunitybio provides regulatory update on anticipated fda submissions in 2025 following meeting with the agency

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a leading immunotherapy company, today announced significant progress in its ongoing discussions with the u.s. food and drug administration (fda) regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer (nmibc) and non-small cell lung cancer (nsclc). nmibc bcg unresponsive papillary disease: immunitybio is preparing to submit a supplemental biologics license application (sbla) in 2025.
IBRX Ratings Summary
IBRX Quant Ranking